-
Mashup Score: 0
Undifferentiated small round cell sarcomas (URCSs) represent a diagnostic challenge and their optimal treatment is unknown. We aimed to define the clinical characteristics, treatment and outcome of URCS patients.
Source: European Journal of CancerCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
Adolescent and young adult (AYA) patients with cancer are poorly recruited to molecularly targeted trials and have not witnessed the advances in cancer treatment and survival seen in other age groups. We report here a pan-European proof-of-concept study to identify actionable alterations in some of the worst prognosis AYA cancers: bone and soft tissue sarcomas.
Source: European Journal of CancerCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Did you read our latest publication on comprehensive molecular profiling of #sarcomas in adolescent and young adult patients? 👉 https://t.co/BIGRlCbuhD @Healthcare_ABC @Winette_vdGraaf @PeterHorak_MD @shenjpat @StefanFrohling #SPECTAplatform #CancerResearch #ClinicalTrials https://t.co/YOOTA0PI2L
-
-
Mashup Score: 0EORTC is 60 - and far from contemplating retirement - 1 year(s) ago
Once they reached the age of 60, many used to start thinking about stopping work or at least reducing its quantity. It would have been easy for EORTCs 60th birthday celebrations in September to become an exercise in self-congratulation, and, indeed, the organisation that gave birth to collaborative clinical research at a European level does have a past to be proud of. For example, without the…
Source: European Journal of CancerCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
EORTC is 60 - and far from contemplating retirement! Did you read @Winette_vdGraaf and Denis Lacombe's article published in the EJC? 👉 https://t.co/n1xHLpuDtq #CancerResearch #ClinicalTrials https://t.co/QDiPKqSUmM
-
-
Mashup Score: 1
Although anti-vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitors (RTKIs) have been tested in patients with neuroendocrine tumors (NETs) over the last 2 decades, no study to date has benchmarked efficacy and toxicity of these drugs in this patient population.
Source: European Journal of CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
Happy to share our meta-analysis assessing efficacy and toxicity of anti-VEGF TKIs in NETs. Not possible with the contributions of some amazing colleagues. @OncologyAdvance @NANETS1 @VUMC_Cancer @VUMCHemOnc @CureNETs https://t.co/BV7z5Q8FdP
-
-
Mashup Score: 0
Background: Combination PARPi plus WEE1i (PARPi + WEE1i) induces replication stress (RS), DNA damage, and abrogates the G2 cell cycle checkpoint. Concurrent PARPi + WEE1i administration effectively inhibits tumor growth but is poorly tolerated. Sequential PARPi+WEE1i administration in vivo mirrors concurrent dosing in cells with high basal RS, while normal cells with low basal RS are protected…
Source: European Journal of CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
NCI10329: Phase Ib STAR Study to investigate the sequential combination of the PARPi olaparib and WEE1i adavosertib in patients with DDR-aberrant advanced tumors, enriched for BRCA1/2 mutated and CCNE1 amplified cancers https://t.co/78Dj57JkAe
-
-
Mashup Score: 3Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study - 1 year(s) ago
Patients with neuroendocrine tumours (NETs) need alternative therapies after failure of first-line therapy.
Source: European Journal of CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study https://t.co/BAl8j0STOF
-
-
Mashup Score: 0
Despite the large number of patients with early breast cancer (EBC) who have been treated with capecitabine in randomised trials, no individual patient data meta-analysis has been conducted. The primary objective was to examine the effect of capecitabine on disease-free survival (DFS), and the secondary objectives were to analyse distant DFS (DDFS), overall survival (OS), pathological complete…
Source: European Journal of CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
Here’s an interesting meta-analysis that I missed reading in the spring: 📖Effects of capecitabine as part of neo-/adjuvant chemotherapy – A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients https://t.co/rTy2WlIluR #bcsm
-
-
Mashup Score: 0Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma - 2 year(s) ago
Recent studies suggest improvements in response to salvage chemotherapy (CT) after immune checkpoint inhibitors (ICIs) in several types of cancer. Our objective was to assess the efficacy of chemotherapy re-challenge after ICI, compared with second-line chemotherapy without previous ICI in patients with locally advanced or metastatic urothelial carcinoma (la/mUC).
Source: European Journal of CancerCategories: Latest Headlines, Oncologists2Tweet-
Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma https://t.co/kuRqAsvDy4
-
-
Mashup Score: 0
To evaluate long-term durability of blinatumomab, a BiTE® (bispecific T-cell engager) molecule, in adults with relapsed/refractory (R/R) Philadelphia chromosome–positive (Ph+) B-cell precursor acute lymphoblastic leukaemia (ALL).
Source: European Journal of CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome–positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study https://t.co/3LHlrCoMHQ #ALL #leusm https://t.co/00J09dLrxU
-
-
Mashup Score: 6
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with dismal prognosis, projected to be the second cause of cancer-related deaths worldwide by 2030 [1]. Most of the patients will present already a locally advanced or metastatic disease at diagnosis and systemic chemotherapy remains their main therapeutical option [2]. In firstline, not only the Folfirinox regimen (5…
Source: European Journal of CancerCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
RT @ArndtVogel: 🔥FGFR2 fusion in metastatic pancreatic ductal adenocarcinoma: Is there hope? 🔥 https://t.co/Pjgui96OTQ ✅4 intersting cases…
-
A large and informative retrospective study about the outcomes of these poorly understood undifferentiated round cell sarcomas (aka non-Ewing). This is now the time for prospective clinical trials. https://t.co/aqbteP71Ab